topic

201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma
Angelica Valadez, Madeleine Welsh, Christine Kim, Angela Johns, Alain Algazi, Hyunseok Kang, Hyunseok Kang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A118; DOI: 10.1136/jitc-2020-SITC2020.0201
203 Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients
Jae-Chul Lee, Woo Seok Yang, Hye-Young Park, Hye-mi Nam, Hyun-Jung Cho, Mi-Young Oh, Eun-Young Kwak, Jinhyun Park, Myeng Eun Jung, Hawook Chung, Minju Kim, Jae-Hwan Kim, Byoung Chul Cho, Jae-Chul Lee

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A119; DOI: 10.1136/jitc-2020-SITC2020.0203
206 An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer
Elizabeth Stirling, Ethan Willey-Shelkey, Adam Wilson, Aleksander Skardal, Pierre Triozzi, Masaki Terabe, Lance Miller, Shay Soker, David Soto-Pantoja

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A121-A122; DOI: 10.1136/jitc-2020-SITC2020.0206
207 Small molecule inhibitors of Sec61 cotranslational translocation regulate the phagocytosis checkpoint molecule CD47
Jennifer Whang, Andrea Fan, Christopher Kirk, Eric Lowe, Dustin McMinn, Beatriz Millare, Meera Rao

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A122; DOI: 10.1136/jitc-2020-SITC2020.0207
209 Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer
Bryan Iorgulescu, Prafulla Gokhale, Maria Speranza, Benjamin Eschle, Michael Poitras, Margaret Wilkens, Kara Soroko, Chhayheng Chhoeu, Aine Knott, Yan Gao, Mary Jane Lim-Fat, Gregory Baker, Dennis Bonal, Quang-Dé Nguyen, Gareth Grant, Keith Ligon, Peter Sorger, E Chiocca, Ana Anderson, Paul Kirschmeier, Arlene Sharpe, Gordon Freeman, David Reardon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A123-A126; DOI: 10.1136/jitc-2020-SITC2020.0209
213 Use of A novel peptide ligand targeting multiple immune checkpoints: a novel approach to immunotherapy against central nervous system tumors
Christopher Moertel, Zhengming Xiong, Michael Olin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A127-A128; DOI: 10.1136/jitc-2020-SITC2020.0213
217 Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development
Yasmin Hashambhoy-Ramsay, Vikki Spaulding, Michelle Priess, Kristin O’Malley, Monica Gostissa, Edward Stack, Jeff Smith, Margaret Willer, Ben Umiker, Donald Shaffer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A129-A130; DOI: 10.1136/jitc-2020-SITC2020.0217
25 Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring
Georges Azzi, Shifra Krinshpun, Antony Tin, Allyson Malashevich, Meenakshi Malhotra, Paul Billings, Angel Rodriguez, Alexey Aleshin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A13-A14; DOI: 10.1136/jitc-2020-SITC2020.0025
24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
Pashtoon Kasi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A13; DOI: 10.1136/jitc-2020-SITC2020.0024
219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients
Ahmad Tarhini, David McDermott, Apoorva Ambavane, Agnes Benedict, Cho-Han Lee, Corey Ritchings, Brian Stwalley, Meredith Regan, Michael Atkins

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A130-A131; DOI: 10.1136/jitc-2020-SITC2020.0219

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages